Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 5/2016

01-05-2016 | Original Article

Correlation of IL-27 genetic polymorphisms with the risk and survival of cervical cancer in a Chinese Han population

Authors: Jian Shi, Meng Yuan, Shuang Liu, Xiaoyang Duan, Juan Chen

Published in: Tumor Biology | Issue 5/2016

Login to get access

Abstract

Interleukin-27 (IL-27) has been recognized as a pleiotropic cytokine with both pro- and anti-inflammatory properties. However, there are no data about the role of IL-27 polymorphism in the development of cervical cancer. A hospital-based case–control study was conducted in 380 patients with cervical cancer and 380 healthy controls to investigate the possible associations of IL-27 gene polymorphisms (−964A/G, 2905T/G, and 4730T/C), with susceptibility to cervical cancer and clinical outcome. Our results suggested that the IL-27 2905T/G was significantly associated with a decreased risk of cervical cancer (TG vs. TT, odds ratio (OR) = 0.77; 95 % confidence interval (CI) = 0.60–0.86; GG vs. TT, OR = 0.95; 95 % CI = 0.72–0.96; TG+GG vs. TT, OR = 0.87; 95 % CI = 0.65–0.94). However, the genotype and allele frequencies of IL-27 (−964A/G and 4730T/C) polymorphisms in cervical cancer patients were not significantly different from controls. Further analysis showed IL-27 2905T/G genotypes were associated with advanced tumor stages of cervical cancer patients. More interestingly, the IL-27 2905T/G genotypes were statistically significantly associated with the survival in cervical cancer patients. Our results showed that the IL-27 2905T/G genotypes were associated with decreased susceptibility and development of cervical cancer in Chinese Han population.
Literature
1.
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.CrossRefPubMed
2.
Liu D, Zhou P, Zhang L, et al. Differential expression of Oct4 in HPV-positive and HPV-negative cervical cancer cells is not regulated by DNA methyltransferase 3A. Tumour Biol. 2011;32:941–50.CrossRefPubMed
3.
4.
Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet. 2007;370:890–907.CrossRefPubMed
5.
Katki HA, Kinney WK, Fetterman B, Lorey T, Poitras NE, Cheung L, et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol. 2011;12:663–72.CrossRefPubMedPubMedCentral
6.
Barbisan G, Perez LO, Contreras A, Golijow CD. TNF-α and IL-10 promoter polymorphisms, HPV infection, and cervical cancer risk. Tumour Biol. 2012;33:1549–56.CrossRefPubMed
7.
Chae SC, Li CS, Kim KM, Yang JY, Zhang Q, et al. Identification of polymorphisms in human interleukin-27 and their association with asthma in a Korean population. J Hum Genet. 2007;52:355–61.CrossRefPubMed
8.
Li CS, Zhang Q, Lee KJ, Cho SW, Lee KM, et al. Interleukin-27 polymorphisms are associated with inflammatory bowel diseases in a Korean population. J Gastroenterol Hepatol. 2009;24:1692–6.CrossRefPubMed
9.
Hunter CA. New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions. Nat Rev Immunol. 2005;5:521–31.CrossRefPubMed
10.
Trinchieri G, Pflanz S, Kastelein RA. The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses. Immunity. 2003;19:641–4.CrossRefPubMed
11.
Huang ZQ, Wang JL, Pan GG, Wei YS. Association of single nucleotide polymorphisms in IL-12 and IL-27 genes with colorectal cancer risk. Clin Biochem. 2012;45:54–9.CrossRefPubMed
12.
Wei YS, Lan Y, Luo B, Lu D, Nong HB. Association of variants in the interleukin-27 and interleukin-12 gene with nasopharyngeal carcinoma. Mol Carcinog. 2009;48:751–7.CrossRefPubMed
13.
Tao YP, Wang WL, Li SY, Zhang J, Shi QZ, et al. Associations between polymorphisms in IL-12A, IL-12B, IL-12Rbeta, 1, IL-27 gene and serum levels of IL-12p40, IL-27p28 with esophageal cancer. J Cancer Res Clin Oncol. 2012;138:1891–900.CrossRefPubMed
14.
Zhang S, Wang Y, Wang M, Ji Z. IL-27 -964A>G polymorphism and the risk of breast cancer: a case-control study. Tumour Biol. 2014;35:12099–102.CrossRefPubMed
15.
Peng Q, Qin X, He Y, Chen Z, Deng Y, et al. Association of IL27 gene polymorphisms and HBV-related hepatocellular carcinoma risk in a Chinese population. Infect Genet Evol. 2013;16:1–4.CrossRefPubMed
16.
Owaki T, Asakawa M, Fukai F, et al. IL-27 induces Th1 differentiation via p38 MAPK/T-bet- and intercellular adhesion molecule-1/LFA-1/ERK1/2-dependent pathways. J Immunol. 2006;177:7579–87.CrossRefPubMed
17.
Miyazaki Y, Inoue H, Matsumura M, et al. Exacerbation of experimental allergic asthma by augmented Th2 responses in WSX-deficient mice. J Immunol. 2005;175:2401–7.CrossRefPubMed
18.
Yoshimoto T, Morishima N, Mizoguchi I, Shimizu M, Nagai H, et al. Antiproliferative activity of IL-27 on melanoma. J Immunol. 2008;180:6527–35.CrossRefPubMed
19.
Ho MY, Leu SJ, Sun GH, Tao MH, Tang SJ, et al. IL-27 directly restrains lung tumorigenicity by suppressing cyclooxygenase-2-mediated activities. J Immunol. 2009;183:6217–26.CrossRefPubMed
Metadata
Title
Correlation of IL-27 genetic polymorphisms with the risk and survival of cervical cancer in a Chinese Han population
Authors
Jian Shi
Meng Yuan
Shuang Liu
Xiaoyang Duan
Juan Chen
Publication date
01-05-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 5/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-4512-x

Other articles of this Issue 5/2016

Tumor Biology 5/2016 Go to the issue

Original Article

Synergistic effect of fisetin combined with sorafenib in human cervical cancer HeLa cells through activation of death receptor-5 mediated caspase-8/caspase-3 and the mitochondria-dependent apoptotic pathway

Original Article

RETRACTED ARTICLE: Downregulation of microRNA-217 and microRNA-646 acts as potential predictor biomarkers in progression, metastasis, and unfavorable prognosis of human osteosarcoma

Original Article

The small conductance calcium-activated potassium channel 3 (SK3) is a molecular target for Edelfosine to reduce the invasive potential of urothelial carcinoma cells

Original Article

In search of underlying mechanisms and potential drugs of melphalan-induced vascular toxicity through retinal endothelial cells using bioinformatics approach

Review

Phenotype of circulating tumor cell: face-off between epithelial and mesenchymal masks

Original Article

Comparative analysis of basaloid and conventional squamous cell carcinomas of the esophagus: prognostic relevance of clinicopathological features and protein expression
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits